Drugs / FMXIN002
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07228325 | Nov 2025 → Mar 2026 overdue | allergic disease, anaphylaxis | Nasus Pharma | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMXIN002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07228325 ↗ |
| Route | Intranasal | “Single dose of FMXIN002 epinephrine microspheres powder for nasal application, 4.0 mg, at normal conditions.” NCT07228325 ↗ |